Enanta Pharmaceuticals Stock News

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reportin

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) was the recipient of a large decline in short interest in October. As of October 29th, there was short interest totalling 1,080,000 shares, a decline of 32.1% from the October 14th total of 1,590,000 shares. Currently, 6.1% of the shares of the stock are short sold. Based on an average daily []

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target cut by JMP Securities from $121.00 to $111.00 in a research report sent to investors on Friday, Price Targets.com reports. They currently have a market outperform rating on the biotechnology companys stock. Several other analysts have also issued reports on the stock. Zacks Investment Research lowered shares of []

Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Participate in December Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus Program

Related Stocks: IAC , ENTA , RGNX , IVV , WH , EOLS , IMCR , FCOB , MRSN , IMUX , BKCC , NEXI , HUM , GRA , ASND , NWHM , MUDS , BPY ,

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta to Host Conference Call on November 22 to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

These biotech stocks have recently been responsible for a slew of rocketship emojis.

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported new preclinical data for EDP-235, its recently announced lead oral protease inhibitor for COVID-19.  The data were presented at the Internati